Summary from Dryad: "Abstract: INTRODUCTION: Lobular carcinoma in situ (LCIS) has been accepted as a marker of risk for the development of invasive breast cancer, yet modern models of breast carcinogenesis include LCIS as a precursor of low-grade carcinomas. We provide evidence favoring a clonal origin for LCIS and synchronous estrogen receptor-positive malignant lesions of the ductal and lobular...

From Dryad summary: "Abstract: The classification of melanoma into four histological subtypes has been questioned regarding its clinical validity in providing relevant information for treatment for metastatic tumors. Specific genetic alterations are associated with particular clinical and histopathological features, suggesting that these could be helpful in refining existing melanoma classification...

This dataset contains genomic profile samples, mutation information, and sequencing data from 218 prostate tumors, including 181 primaries and 37 metastases, and 14 prostate cancer cell lines and xenografts. After generating a map of CNAs across the dataset, the authors of this study used matching mRNA and microRNA transcriptome and exon resequencing data to define the frequency of alterations in...

Description from PRIDE: "To find differentially expressed protein in colorectal cancer compared with normal colon tissue, we performed global proteome analysis using LC-MS."

Description from PRIDE: "To find differentially expressed protein in colorectal cancer compared with normal colon tissue, we performed global proteome analysis using LC-MS."

Summary from GEO: "Prostate cancer is the most common malignancy in men. Yet, the modest benefit of treatment highlights the unmet need for prognostic biomarkers in prostate cancer (1). Few large prostate oncogenome resources currently exist that combine the molecular and clinical outcome data necessary for prognostic discovery. To determine the extent to which genomic aberrations reflect the risk...

Description from Zenodo: "Processed metabolomics and sample data associated with "Immunometabolic coevolution defines unique microenvironmental niches in ccRCC"."

Description from EGA: "CM214 - Biomarker Analysis From the Phase 3 CheckMate 214 Trial of Nivolumab Plus Ipilimumab (N+I) or Sunitinib (S) in Advanced Renal Cell Carcinoma (aRCC)" Anonymized raw FASTQ files of WES and RNA-seq data from 87 patients who granted informed consent to share such data, are made available at the European Genome-Phenome Archive (EGA)